Key result
Abiraterone acetate reduced the risk of death by 19.4% (HR 0.806) compared to placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
Why the study?
Does an invasive strategy (PCI) improve outcomes compared to conservative management in an advanced cancer patient presenting with NSTEMI?
RCT (n=1,088)
Placebo-controlled
Randomized
Yes
Does an invasive strategy (PCI) improve outcomes compared to conservative management in an advanced cancer patient presenting with NSTEMI?
Hazard Ratio: 0.806 (95% CI 0.697–0.931)
Absolute Event Rate: 65% vs 71%
p-value: p=0.0033
This case highlights the complex decision-making between conservative and invasive strategies for NSTEMI in patients with advanced cancer, where competing risks like bleeding and cancer progression strongly influence outcomes.
Case highlights individualized NSTEMI decisions amid competing cancer risks; leaves open whether PCI improves outcomes over conservative care.
We present the case of a 70-year-old male patient with metastatic and castration-resistant prostate cancer as well as advanced bladder cancer, who suffered a non-ST-elevation myocardial infarction (NSTEMI). The cause of ischemia was critical left main stem stenosis, and right coronary artery stenosis. Initially, the patient was qualified for conservative treatment, but due to the intensifying symptoms of myocardial ischemia, it was decided that a hemodynamic intervention was necessary. Two drug-eluting stents were implanted, leading to clinical improvement. Following the treatment, the patient was considered as a candidate for further anti-cancer therapy. Unfortunately, due to the bladder cancer progression, anaemia and haemorrhage, his clinical condition exacerbated, and the patient died about 1 month from the cardiac intervention. Apart from the case description, the paper includes a review of literature on the treatment of acute coronary syndromes without ST-segment elevation in cancer patients.
No takes yet. Share an insight, caveat, or question.
Wilk et al. (2018) conducted an RCT in Metastatic castration-resistant prostate cancer (n=1,088). Abiraterone acetate vs. Placebo was evaluated on Overall survival (HR 0.806, 95% CI 0.697-0.931, p=0.0033). Abiraterone acetate reduced the risk of death by 19.4% (HR 0.806) compared to placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: